Review and prospects of targeted therapies for Spleen tyrosine kinase (SYK)

被引：11

作者：

Wang, Zhaozhao ^{[1
]}

Qu, Shu ^{[1
]}

Yuan, Jiahao ^{[1
]}

Tian, Wen ^{[1
]}

Xu, Jinglei ^{[1
]}

Tao, Rui ^{[1
]}

Sun, Shilong ^{[1
]}

Lu, Tao ^{[1
,2
]}

Tang, Weifang ^{[1
]}

Zhu, Yong ^{[1
]}

机构：

[1] China Pharmaceut Univ, Sch Sci, 639 Longmian Ave, Nanjing 211198, Peoples R China

[2] China Pharmaceut Univ, State Key Lab Nat Med, 24 Tongjiaxiang, Nanjing 210009, Peoples R China

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2023年 / 96卷

关键词：

Spleen tyrosine kinase; Inhibitors; SYK PROTACs; PHORCs; B-CELL RECEPTOR; CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTIGEN RECEPTOR; MAST-CELLS; NEGATIVE REGULATION; THERAPEUTIC TARGET; IGE RECEPTOR; INHIBITOR; ACTIVATION; AUTOIMMUNE;

D O I：

10.1016/j.bmc.2023.117514

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Spleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase. The dysregulation of SYK is closely related to the occurrence and development of allergic diseases, autoimmune diseases and cancer. SYK has become an attractive target for drug discovery due to its important biological functions. This article reviews the biological function of SYK, the relationship between SYK and disease, and therapies targeting SYK. In addition, inspired by new technologies such as proteolysis targeting chimeras (PROTACs) and phosphatase recruiting chimeras (PHORCs), we propose the development of new therapeutic approaches for targeting SYK, such as SYK PROTACs and SYK PHORCs, which may overcome deficiencies of existing methods.

引用

页数：17

共 139 条

[1]

Abram Clare L, 2007, Sci STKE, V2007, pre2, DOI 10.1126/stke.3772007re2

[2] Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk [J].

Abtahian, F ;

Guerriero, A ;

Sebzda, E ;

Lu, MM ;

Zhou, R ;

Mocsai, A ;

Myers, EE ;

Huang, B ;

Jackson, DG ;

Ferrari, VA ;

Tybulewicz, V ;

Lowell, CA ;

Lepore, JJ ;

Koretzky, GA ;

Kahn, ML .

SCIENCE, 2003, 299 (5604) :247-251

[3] The sickening consequences of too much SYK signaling [J].

Aksentijevich, Ivona .

NATURE GENETICS, 2021, 53 (04) :432-434

[4] Inhibition of spleen tyrosine kinase attenuates psoriasis-like inflammation in mice through blockade of dendritic cell-Th17 inflammation axis [J].

Alzahrani, Khalid S. ;

Nadeem, Ahmed ;

Ahmad, Sheikh F. ;

Al-Harbi, Naif O. ;

Ibrahim, Khalid E. ;

El-Sherbeeny, Ahmad M. ;

Alhoshani, Ali R. ;

Alshammari, Musaad A. ;

Alotaibi, Moureq R. ;

Al-Harbi, Mohammed M. .

BIOMEDICINE & PHARMACOTHERAPY, 2019, 111 :347-358

[5] An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management [J].

Ameer, Muhammad Atif ;

Chaudhry, Haroon ;

Mushtaq, Javaria ;

Khan, Osama S. ;

Babar, Maham ;

Hashim, Tehmina ;

Zeb, Saima ;

Tariq, Muhammad Ali ;

Patlolla, Sridhar Reddy ;

Ali, Junaid ;

Hashim, Syeda Nafeesa ;

Hashim, Sana .

CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (10)

[6] Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia [J].

Bartaula-Brevik, Sushma ;

Brattas, Marte Karen Lindstad ;

Tvedt, Tor Henrik Anderson ;

Reikvam, Hakon ;

Bruserud, Oystein .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (04) :377-387

[7]

Bashore FM, 2023, bioRxiv

[8] PROTAC targeted protein degraders: the past is prologue [J].

Bekes, Miklos ;

Langley, David R. ;

Crews, Craig M. .

NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (03) :181-200

[9] Atopic dermatitis [J].

Boguniewicz, M ;

Leung, DYM .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) :S475-S480

[10] Regulatory interplay between Vav1, Syk and β-catenin occurs in lung cancer cells [J].

Boudria, Rofia ;

Lauriente, Vanessa ;

Oudar, Antonin ;

Harouna-Rachidi, Souleymane ;

Dondi, Elisabetta ;

Le Roy, Christine ;

Gardano, Laura ;

Varin-Blank, Nadine ;

Guittat, Lionel .

CELLULAR SIGNALLING, 2021, 86

← 1 2 3 4 5 6 7 8 9 10 →